The estimated Net Worth of Laura Clague is at least $2.45 Milion dollars as of 27 April 2022. Ms. Clague owns over 50,000 units of Retrophin stock worth over $19,902 and over the last 13 years she sold RTRX stock worth over $1,130,445. In addition, she makes $1,303,580 as Chief Financial Officer a Senior Vice President at Retrophin.
Laura has made over 15 trades of the Retrophin stock since 2013, according to the Form 4 filled with the SEC. Most recently she exercised 50,000 units of RTRX stock worth $66,500 on 27 April 2022.
The largest trade she's ever made was exercising 50,000 units of Retrophin stock on 27 April 2022 worth over $66,500. On average, Laura trades about 4,001 units every 73 days since 2012. As of 27 April 2022 she still owns at least 284,311 units of Retrophin stock.
You can see the complete history of Ms. Clague stock trades at the bottom of the page.
Laura M. Clague, CPA is the Senior Vice President and Chief Financial Officer of the Company. Ms. Clague previously served as the Chief Financial Officer of the San Diego and Ohio operations of Amylin Pharmaceuticals, Inc., a wholly owned subsidiary of Bristol-Myers Squibb. Prior to the acquisition by Bristol-Myers Squibb in 2012, Ms. Clague was the Vice President, Corporate Controller and Chief Accounting Officer of Amylin for 10 years, and during this time also served as the Chief Financial Officer of the Amylin/Lilly Collaboration. From 1988 to 1999, Ms. Clague was the director of finance and accounting operations for Sony Electronics, Inc. From 1985 to 1988, Ms. Clague served as internal audit supervisor at Cubic Corporation. From 1982 to 1985, Ms. Clague held various audit positions at KPMG. Ms. Clague also serves on the Board of Directors of Genasys Inc. (formerly LRAD Corporation) where she chairs the Audit Committee and is on the Nominating and Governance Committee and she is also a board member of Fluidigm Corporation where she serves on the Audit Committee. Ms. Clague is a certified public accountant in the State of California, and has a B.S. in Business Administration from Menlo College.
As the Chief Financial Officer a Senior Vice President of Retrophin, the total compensation of Laura Clague at Retrophin is $1,303,580. There are 5 executives at Retrophin getting paid more, with Eric Dube having the highest compensation of $9,679,320.
Laura Clague is 61, she's been the Chief Financial Officer a Senior Vice President of Retrophin since 2014. There are 3 older and 11 younger executives at Retrophin. The oldest executive at Retrophin, Inc. is Gary Lyons, 68, who is the Independent Chairman of the Board.
Laura's mailing address filed with the SEC is 16262 WEST BERNARDO ROAD, , SAN DIEGO, CA, 92127.
Over the last 12 years, insiders at Retrophin have traded over $26,547,782 worth of Retrophin stock and bought 585,006 units worth $5,991,663 . The most active insiders traders include Martin Shkreli, Ron Squarer a Steve Aselage. On average, Retrophin executives and independent directors trade stock every 23 days with the average trade being worth of $1,651. The most recent stock trade was executed by Laura Clague on 23 November 2020, trading 7,500 units of RTRX stock currently worth $174,675.
Retrophin, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. Its products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 8, 2008 and is headquartered in San Diego, CA.
Retrophin executives and other stock owners filed with the SEC include: